scroll
LEARN MORE
Buy Hold Sell: The best and worst performers of FY25
Close
Tuesday 5th August – Dow up +585 pts, SPI up +86pts
Close
Monday 4th August – ASX -15pts, BPT, EDV, DHG
Close
14 DAYS FREE ACCESS
Join Market Matters and get full access
to all our Opinion + Action
NVO US $48.81
20 MINUTE DELAYED
ANALYSIS
OPINION
ACTION
i
PERFORMANCE
i
| SHARE PRICE ACTIVITY | |
|---|---|
| Last (Price) | 48.81 |
| Change | 0.00 (0.00) |
| Bid / Ask | 48.17 - 48.21 |
| Volume | 111,010 |
| Turnover | 2,363,511 |
| Open | 0.00 |
| Day Range | 48.36 - 49.21 |
| VWAP | 0.00 |
| Prev Close | 48.81 |
| Last Trade |
i
| KEY INFORMATION | |
|---|---|
| Sector | Healthcare |
| Shares Issued | 3,136,564,503 |
| NTA/Share | 0.00 |
| Last Dividend | 1.66 |
| Dividend Ex Date | 31 MAR 2025 |
| Dividend Pay Date | 08 APR 2025 |
i
| CURRENT () | |
|---|---|
| Revenue | 290,403.00 |
| EBITDA | 147,446.00 |
| Profit | 100,988.00 |
| Earnings Per Share (EPS) | 0 |
| Dividend Per Share (DPS) | 0 |
| Yield % | 3.40 |
| Market Cap | 0 |
| Price to Earnings Ratio (P/E) | 14.3368 |
i
TARGET PRICE FORECAST
i
| ESTIMATES () | |
|---|---|
| Revenue | 312,652.01 |
| EBITDA | 158,003.32 |
| Profit | 113,043.73 |
| Earnings Per Share (EPS) | 24.83 |
| Dividend Per Share (DPS) | 12.38 |
i
BROKER CONSENSUS RECOMMENDATION
BUY
SELL
Target Price
0.00
Lt Growth Rate
0.00
Recommendation (HOLD)
2.62
Business Summary
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Relevant suggested news and content from the site
Video
WATCH
Buy Hold Sell: The best and worst performers of FY25
James Gerrish & Henry Jennings
Podcast
LISTEN
Tuesday 5th August – Dow up +585 pts, SPI up +86pts
Daily Podcast Direct from the Desk
Podcast
LISTEN
Monday 4th August – ASX -15pts, BPT, EDV, DHG
Daily Podcast Direct from the Desk
Only available to Members
Take a free 14 day Market Matters trial – full access to all our reports, portfolios, positions, buy and sell recommendations. Access the latest views on the latest developments from professional money managers. It's free and no payment details are required
For membership options and pricing.
Click here
